94. Primary sclerosing cholangitis
134 clinical trials, 105 drugs (DrugBank: 37 drugs), 18 drug target genes, 131 drug target pathways
Searched query = "Primary sclerosing cholangitis", "PSC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-000204-14-AT (EUCTR) | 13/12/2019 | 26/06/2019 | A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Sclerosing Cholangitis Without Cirrhosis | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor inNon-Cirrhotic Subjects with Primary Sclerosing Cholangitis. | Primary Sclerosing Cholangitis MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: Cilofexor Product Code: GS-9674 INN or Proposed INN: Cilofexor Other descriptive name: GS-9674 Product Name: Cilofexor Product Code: GS-9674 INN or Proposed INN: Cilofexor Other descriptive name: GS-9674 | Gilead Sciences, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 400 | Phase 3 | United States;Finland;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Australia;Denmark;Germany;Netherlands;Japan;New Zealand;Sweden | ||
| 2 | EUCTR2019-000204-14-DK (EUCTR) | 08/11/2019 | 08/07/2019 | A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Sclerosing Cholangitis Without Cirrhosis | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor inNon-Cirrhotic Subjects with Primary Sclerosing Cholangitis. | Primary Sclerosing Cholangitis MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: Cilofexor Product Code: GS-9674 INN or Proposed INN: Cilofexor Other descriptive name: GS-9674 Product Name: Cilofexor Product Code: GS-9674 INN or Proposed INN: Cilofexor Other descriptive name: GS-9674 | Gilead Sciences, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 400 | Phase 3 | United States;Finland;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Denmark;Australia;Germany;Netherlands;Japan;New Zealand;Sweden | ||
| 3 | NCT04060147 (ClinicalTrials.gov) | October 17, 2019 | 15/8/2019 | Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis | A Proof-of-Concept, Open-Label Study Evaluating the Safety and Tolerability of Cilofexor in Subjects With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis | Primary Sclerosing Cholangitis;Compensated Cirrhosis | Drug: CILO | Gilead Sciences | NULL | Recruiting | 18 Years | 75 Years | All | 20 | Phase 1 | United States |
| 4 | EUCTR2019-000204-14-FI (EUCTR) | 11/09/2019 | 24/06/2019 | A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Sclerosing Cholangitis Without Cirrhosis | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor inNon-Cirrhotic Subjects with Primary Sclerosing Cholangitis. | Primary Sclerosing Cholangitis MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: Cilofexor Product Code: GS-9674 INN or Proposed INN: Cilofexor Other descriptive name: GS-9674 Product Name: Cilofexor Product Code: GS-9674 INN or Proposed INN: Cilofexor Other descriptive name: GS-9674 | Gilead Sciences, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 400 | Phase 3 | United States;Finland;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Australia;Denmark;Germany;Netherlands;Japan;New Zealand;Sweden | ||
| 5 | EUCTR2019-000204-14-ES (EUCTR) | 29/08/2019 | 12/09/2019 | A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Sclerosing Cholangitis Without Cirrhosis | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 inNon-Cirrhotic Subjects with Primary Sclerosing Cholangitis. | Primary Sclerosing Cholangitis MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Code: GS-9674 INN or Proposed INN: Cilofexor Other descriptive name: GS-9674 Product Code: GS-9674 INN or Proposed INN: Cilofexor Other descriptive name: GS-9674 | Gilead Sciences, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 400 | Phase 3 | United States;Finland;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Australia;Denmark;Germany;Netherlands;Japan;New Zealand;Sweden | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2019-000204-14-GB (EUCTR) | 15/07/2019 | 27/06/2019 | A study to assess the safety and efficacy of a new investigational drug in subjects with Primary Sclerosing Cholangitis Without Cirrhosis | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: Cilofexor Product Code: GS-9674 INN or Proposed INN: Cilofexor Other descriptive name: GS-9674 Product Name: Cilofexor Product Code: GS-9674 INN or Proposed INN: Cilofexor Other descriptive name: GS-9674 | Gilead Sciences, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 400 | Phase 3 | United States;Finland;Spain;Austria;Israel;Switzerland;United Kingdom;Italy;France;Canada;Belgium;Australia;Denmark;Germany;Netherlands;Japan;New Zealand;Sweden | ||
| 7 | NCT03890120 (ClinicalTrials.gov) | March 27, 2019 | 25/3/2019 | Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | Drug: Cilofexor;Drug: Placebo | Gilead Sciences | NULL | Recruiting | 18 Years | 75 Years | All | 400 | Phase 3 | United States;Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;New Zealand;Spain;Switzerland;United Kingdom |
| 8 | NCT02943460 (ClinicalTrials.gov) | November 29, 2016 | 13/6/2016 | Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis | A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis | Primary Sclerosing Cholangitis | Drug: Cilofexor;Drug: Placebo to match Cilofexor | Gilead Sciences | NULL | Completed | 18 Years | 70 Years | All | 52 | Phase 2 | United States;Austria;Canada;United Kingdom |
| 9 | NCT02808312 (ClinicalTrials.gov) | July 13, 2016 | 17/6/2016 | Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function | A Phase 1 Open-Label, Parallel-Group, Adaptive, Single-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of GS-9674 in Subjects With Normal and Impaired Hepatic Function | Nonalcoholic Steatohepatitis (NASH);Primary Sclerosing Cholangitis (PSC) | Drug: Cilofexor | Gilead Sciences | NULL | Completed | 18 Years | N/A | All | 57 | Phase 1 | United States;New Zealand |